US-India Business Council President Atul Keshap believes a trade deal is close. He notes ongoing talks and a US tariff proposal are part of...

Harvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...

A new gene editing medicine, VERVE-102, offers hope for millions with heart conditions. Eli Lilly's drug showed significant reductions in b...

In India, individuals with diabetes face a significant risk of cardiovascular disease, necessitating proactive heart health management. Too...

Heart disease is on the rise in India. Sales of heart medicines have increased significantly. This growth is attributed to better awareness...

Heart disease is increasing in India. This is boosting sales of cardiac drugs. Sales have risen nearly 50% in five years. Younger people ar...

Novartis introduces a financing scheme with Pine Labs for its cholesterol-lowering drug, Sybrava (inclisiran), in India, aiming to broaden ...

A new report reveals concerning health trends in India, with 45% of the population categorized as "unhealthy" in 2023. The GOQii India Fit ...

LAI has been advocating for regular lipid profile screenings from the age of 20, and from the age of two for those with a family history of...

The most common mental health issues plaguing corporate India are depression, emotional turmoil, insomnia and anxiety, respectively. Men ar...

The study was conducted on 2.66 million people of ages 20 and above across 250 cities.

The Mumbai-based drug major said one of its wholly-owned subsidiaries plans to launch a first-in-class oral drug, Bempedoic Acid, in India ...

Oxford University and AstraZeneca will be sharing their data from phase-I trial of their much-touted Covid-19 vaccine candidate on July 20....

High blood pressure and blood sugar, smoking and pollution are causing more deaths in India than under-nutrition and tropical diseases.

The largest ever analysis on the use of a polypill in cardiovascular disease shows potential for improvements in patient care, researchers ...

Cholesterol-reducing drugs worth nearly $15 billion (Rs 92,000 crore) were sold in the US in the year to September 2013, Bakhru wrote in hi...

"Lupin Pharmaceuticals Inc (LPI), the company's US subsidiary would commence marketing the product shortly," Lupin said.